Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Asset Writedowns and Impairment (2022)

UroGen Pharma (URGN) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $255000.0 as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Asset Writedowns and Impairment changed N/A year-over-year to $255000.0, compared with a TTM value of $605000.0 through Dec 2023, changed 0.0%, and an annual FY2022 reading of $870000.0, changed N/A over the prior year.
  • Asset Writedowns and Impairment was $255000.0 for Q4 2022 at UroGen Pharma, down from $350000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $350000.0 in Q3 2022 and bottomed at $255000.0 in Q4 2022.